cardiovascular disease

BMS, Avidity add another link to cardiovascular partnership with $100M expansion
BMS, Avidity add another link to cardiovascular partnership with $100M expansion
Fierce Biotech
Bristol Myers Squibb
Avidity Biosciences
R&D
cardiovascular disease
Flag link:
Novo Nordisk says Wegovy can help heart disease patients—and not just because it produces weight loss
Novo Nordisk says Wegovy can help heart disease patients—and not just because it produces weight loss
Fierce Pharma
Novo Nordisk
Wegovy
heart disease
cardiovascular disease
clinical trials
Flag link:
AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
Pharmaphorum
Eli Lilly
AHA
siRNA
lipoprotein(a)
cardiovascular disease
lepodisiran
Flag link:
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
Stat
Wegovy
Novo Nordisk
clinical trials
cardiovascular disease
Flag link:
Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling
Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling
Fierce Biotech
Merck
sotatercept
FDA
cardiovascular disease
Flag link:
Wegovy costs $1.1m to prevent one heart attack, stroke, or cardiovascular death
Wegovy costs $1.1m to prevent one heart attack, stroke, or cardiovascular death
Airfinity
Novo Nordisk
Wegovy
Ozempic
cardiovascular disease
Flag link:
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Amgen
cardiovascular disease
olpasiran
clinical trials
Flag link:
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Fierce Biotech
Merck
PCSK9 inhibitors
clinical trials
cardiovascular disease
cholesterol
MK-0616
Flag link:
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
Motley Fool
Novo Nordisk
Ozempic
diabetes
weight loss
liver disease
addiction
cardiovascular disease
Flag link:
Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy
Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy
Fierce Pharma
Novo Nordisk
Wegovy
clinical trials
cardiovascular disease
obesity
Flag link:
Statins reduce cardiovascular risk in people living with HIV, new global study finds
Statins reduce cardiovascular risk in people living with HIV, new global study finds
Stat
statins
HIV
cardiovascular disease
Flag link:
Pfizer spies cardiovascular potential in Riparian preclinical licensing agreement
Pfizer spies cardiovascular potential in Riparian preclinical licensing agreement
Fierce Biotech
Pfizer
Riparian Pharmaceuticals
cardiovascular disease
Flag link:
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
BioSpace
Novartis
earnings
solid tumors
hematology
immunology
Neuroscience
cardiovascular disease
Flag link:
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Yahoo Finance
Ionis Pharmaceuticals
clinical trials
cardiovascular disease
pelacarsen
Flag link:
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
MedCity News
Novartis
Anumana
artificial intelligence
diagnostics
cardiovascular disease
Flag link:
Cytokinetics aims to become the Vertex of cardiovascular disease
Cytokinetics aims to become the Vertex of cardiovascular disease
EP Vantage
Cytokinetics
Amgen
heart failure
Omecamtiv Mecarbil
cardiovascular disease
Flag link:
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Pharmaforum
Amgen
olpasiran
Novartis
clinical trials
cardiovascular disease
Flag link:
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytruda
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytruda
Fierce Biotech
Merck
Keytruda
cardiovascular disease
Flag link:
Bayer, One Drop launch AI tool for heart disease prevention
Bayer, One Drop launch AI tool for heart disease prevention
Pharmaforum
Bayer
One Drop
digital health
artificial intelligence
cardiovascular disease
Flag link:
7 Moments in 2021 Destined to Change the Cardio-Device Industry Forever
7 Moments in 2021 Destined to Change the Cardio-Device Industry Forever
Medical Devices and Diagnostics Industry
devices
cardiovascular disease
Medtronic
LivaNova
Google
AliveCor
Abbott Labs
Flag link:

Pages